Table 2.
Treatment exposure and reasons for discontinuation in integrated safety analysis
Ibrutinib (N = 330) | |
---|---|
Treatment exposure | |
Exposure, median (range), mo | 29.0 (0.2-42.9) |
Duration of treatment, mo | |
≤6 | 32 (10) |
>6 to 12 | 18 (5) |
>12 to 24 | 34 (10) |
>24 to 36 | 193 (58) |
>36 | 53 (16) |
Treatment discontinuation | 124 (38) |
PD | 52 (16) |
AE | 37 (11) |
Death | 18 (5) |
Physician decision | 9 (3) |
Withdrawal by patient | 8 (2) |
Unless otherwise noted, all data are n (%).